Raymond James analyst John Ransom lowered the firm’s price target on Cigna (CI) to $360 from $415 and keeps a Strong Buy rating on the shares.
Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, as ...
Cigna Group CEO David Cordani said the company will make investments this year to improve patient and provider experiences ...
Cantor Fitzgerald lowered the firm’s price target on Cigna (CI) to $350 from $400 and keeps an Overweight rating on the shares. Cantor is ...
Cigna blamed lower-than-expected fourth-quarter returns on its stop-loss insurance business that insures employers from ...
Cigna Group plans to limit patients’ out-of-pocket expenses for medications as the insurer faces pressure from Washington ...
Cigna (CI) stock falls as the managed care company's Q4 2024 earnings miss the consensus due to an unexpected rise in medical ...
Cigna Group shares fell sharply after the health insurer reported fourth-quarter profit that was dragged down by medical ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.
Shares of Cigna ( CI -8.00%) were dropping Thursday. The stock was down 8.4% as of 1:20 p.m. ET but had lost as much as 11.3% ...
Bloomfield-based Cigna announced this week a new initiative that aims to reduce out-of-pocket prescription-drug costs and make those costs more transparent.
The villains were injectable specialty drugs like Keytruda and inpatient surgical procedures for seriously ill patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback